Physician profile
Deepak Shivaram
NPI 1588655450
$12,621.78
in general payments reported to CMS, 2019-2025
24 companies · $1,128 in 2025
The $1,128 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,152 · 2020: $828 · 2021: $1,208 · 2022: $2,415 · 2023: $1,892 · 2024: $1,999 · 2025: $1,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,018.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,117.01 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,669.08 | 2019-2025 | Ozempic |
| Glaxosmithkline, LLC. | $1,446.35 | 2019-2024 | Arexvy |
| Amgen INC. | $1,291.60 | 2019-2024 | Tepezza, Repatha |
| Gilead Sciences, INC. | $1,169.18 | 2021-2024 | Epclusa, Vemlidy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,156.68 | 2019-2025 | Jardiance |
| Abbvie INC. | $920.87 | 2019-2023 | Linzess |
| Lilly USA, LLC | $485.14 | 2019-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $328.50 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $275.00 | 2019 | |
| Pfizer INC. | $250.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $231.27 | 2022-2023 | |
| Madrigal Pharmaceuticals | $134.40 | 2025 | Rezdiffra |
| Abbott Laboratories | $133.36 | 2022 | |
| Amarin Pharma, INC. | $125.00 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $125.00 | 2020 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $124.99 | 2022 | |
| Nestle Healthcare Nutrition INC. | $116.42 | 2023 | |
| Radius Health, INC. | $100.03 | 2019 | |
| Sunovion Pharmaceuticals INC. | $96.12 | 2019 | |
| Smith+Nephew, INC. | $94.77 | 2019 | |
| Nevro Corp. | $86.26 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.75 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Shivaram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.